ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Geriatrics · Lancet Healthy Longev · 2026-08-11

In 1160 adults aged 75+ taking statins for primary prevention, stopping statins was non-inferior to continuing for 3-year all-cause mortality (7·2% vs 7·9%; difference -0·68%, 95% CI -3·95 to 2·60; margin 5%). Adverse events were similar (74·0% vs 73·1%).

RCTn = 1,180
Bonnet et al. Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial
Cardiology · Lancet · 2026-02-05

Meta-analysis of individual data from 19 double-blind trials (123,940 participants) of statin vs placebo: besides known muscle and diabetes effects, only 4 of 66 label-listed adverse outcomes were excess, eg abnormal liver transaminases 0.30% vs 0.22% per year (RR 1.41).

Meta-analysisn = 123,940
Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: [email protected] et al. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.